Do schizophrenia and bipolar disorders share a common disease susceptibility variant at the MMP3 gene?

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 33, Issue 3, 2009, Pages 557-561

  Kucukali, Cem Ismail ^a   Aydin, Makbule ^b   Ozkok, Elif ^b   Bilge, Emine ^b   Orhan, Nurcan ^b   Zengin, Asli ^b   Kara, Ihsan ^b  

^a Istanbul Erenkoy Psychiatric and Neurological Disorders Hospital   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

Bipolar disorders; MMP3; Polymorphism; Schizophrenia

Indexed keywords

STROMELYSIN;

ADULT; ARTICLE; BIPOLAR DISORDER; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; SCHIZOPHRENIA;

ADULT; BIPOLAR DISORDER; CHI-SQUARE DISTRIBUTION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LINKAGE (GENETICS); MALE; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; SCHIZOPHRENIA;

EID: 62849114120     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2009.02.012     Document Type: Article

References (60)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental disorder. American Psychiatric Association. 4th ed. Washington DC: American Psychiatric Pres; 1994.
2. Andreasan N.C. Methods for assessing positive and negative symptoms. Mod Probl Pharmacopsychiatry 24 (1990) 73-88
3. Asundi V.K., Erdman R., Stahl R.C., and Carey D.J. Matrix metalloproteinase-dependent shedding of syndecan-3, a transmembrane heparan sulfate proteoglycan, in Schwann cells. J Neurosci Res 73 (2003) 593-602
4. Bender H.U., Almashanu S., Steel G., Hu C.A., Lin W.W., Willis A., et al. Functional consequences of PRODH missense mutations. Am J Hum Genet 76 (2005) 409-420
5. Dityatev A., and Schachner M. Extracellular matrix molecules and synaptic plasticity. Nat Rev Neurosci 4 (2003) 456-468
6. Dzwonek J., Rylski M., and Kaczmarek L. Matrix metalloproteinases and their endogenous inhibitors in neuronal physiology of the adult brain. FEBS Lett 567 (2004) 129-135
7. Erkoc S., Arkonac O., Atakli C., and Ozmen E. Pozitif Semptomlari Degerlendirme Ölçeginin güvenilirligi ve geçerliligi. Düsünen Adam 4 (1991) 20-24
8. Erkoc S., Arkonac O., Atakli C., and Özmen E. Negatif Semptomlari Degerlendirme Ölçeginin güvenilirligi ve geçerliligi. Düsünen Adam 4 (1991) 16-19
9. Fatemi S.H., Stary J.M., Halt A., and Realmuto G. Dysregulation of reelin and Bcl-2 in autistic cerebellum. J Autism Dev Disord 31 (2001) 529-535
10. Fatemi S.H., Stary J.M., Earle J.A., Araghi-Niknam M., and Eagan E. GABAergic dysfunction in schizophrenia and mood disorders as reflected by decreased levels of glutamic acid decarboxylase 65 and 67 kDa and reelin proteins in cerebellum. Schizophr Res 72 (2005) 109-122
11. First M.B., Spitzer R.L., and Williams J.B.W. Structured Clinical Interview for DSM-IV CID (1997), American Psychiatric Association, Washington DC
12. Girolamo F., Virgintino D., Errede M., Capobianco C., Bernardini N., Bertossi M., et al. Involvement of metalloproteinase-2 in the development of human brain microvessels. Histochem Cell Biol 122 (2004) 261-270
13. Harkness K.A., Adamson P., Sussman J.D., Davies-Jones G.A., Greenwood J., and Woodroffe M.N. Dexamethasone regulation of matrix metalloproteinase expression. Brain 123 (2000) 698-709
14. Harrison P.J., and Weinberger D.R. Schizophrenia genes, gene expression, and neuropathology: on the matter of their convergence. Mol Psychiatry 10 (2005) 40-68
15. Hayashita-Kinoh H., Kinoh H., Okada A., Kamori K., Itoh Y., Chiba T., et al. Membrane-type 5 matrix metalloproteinase is expressed in differentiated neurons and regulates axonal growth. Cell Growth Differ 12 (2001) 573-580
16. Helbecque N., Hermant X., Cottel D., and Amouyel P. The role of matrix metalloproteinase-9 in dementia. Neurosci Lett 350 (2003) 181-183
17. Ito S., Kimura K., Haneda M., Ishida Y., Sawada M., and Isobe K. Induction of matrix metalloproteinases (MMP3, MMP12 and MMP13) expression in the microglia by amyloid- β stimulation via the P13K/Akt pathway. Exp Gerontology 42 (2007) 532-537
18. Jablensky A., Sartorius N., Ernberg G., Anker M., Karten A., Cooper J.E., et al. Schizophrenia: Manifestations, incidence and course in different cultures. A World Health Organization ten-country study. Psychol Med Monogr Suppl 120 (1992) 1-97
19. Jung S.S., Zhang W., and van Nostrand W.E. Pathogenic A beta induces the expression and activation of matrix metalloproteinase-2 in human cerebrovascular smooth muscle cells. J Neurochem 85 (2003) 1208-1215
20. Karadag F., Oral E.T., Aran Yalcin F., Erten E., et al. Reliability and validity of Turkish translation of Young Mania Rating Scale. Türk Psikiyatri Dergisi 13 (2002) 107-114
21. Kessler R.C., Mc Gonagle K.A., Zhao S., Nelson C.B., Hughes M., Eshleman S., et al. Life-time and 12 month prevalence of DSM-II-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 51 (1994) 8-19
22. Kieseier B.C., Seifert T., Giovannoni G., and Hartung H.P. Matrix metalloproteinases in inflammatory demyelination: targets for treatment. Neurology 53 (1999) 20-25
23. Kim H.J., Fillmore H.L., Reeves T.M., and Phillips L.L. Elevation of hippocampal MMP-3 expression and activity during trauma-induced synaptogenesis. Exp Neurol 192 (2005) 60-72
24. Laviola G., Adriani W., Gaudino C., Marino R., and Flavio K. Paradoxical effects of prenatal acetyl cholinesterase blockade on neurobehavioral development and drug-induced stereotypies in reeler mice. Psychopharmacology (Berlin) 184 (2006) 155-165
25. Magaro P.A., Abrams L., and Cantrell P. The Maine Scale of Paranoid and Nonparanoid Schizophrenia: reliability and validity. J Consul Clin Psychol 49 (1981) 438-447
26. Maier W., Zobel A., and Wagner M. Schizophrenia and bipolar disorder: differences and overlaps. Curr Opin Psychiatry 19 (2006) 165-170
27. Martino D.J., Marengo E., Igoa A., Scapola M., Ais E.D., Perinot L., et al. Neurocognitive and symptomatic predictors of functional outcome in bipolar disorders: a prospective 1 year follow-up study. J Affect Disord (2008) doi:10.1016/j.jad.2008.10.023
28. Meighan S.E., Meighan P.C., Choudhury P., et al. Effects of extracellular matrix-degrading proteases matrix metalloproteinases 3 and 9 on spatial learning and synaptic plasticity. J Neurochem 96 (2006) 1227-1241
29. Mercapide J., Lopez De Cicco R., Castresana J.S., and Klein-Szanto A.J. Stromelysin-1/matrix metalloproteinase-3 (MMP-3) expression accounts for invasive properties of human astrocytoma cell lines. Int J Cancer 106 (2003) 676-682
30. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
31. Nagy V., Bozdagi O., Matynia A., Balcerzyk M., Okulski P., Dzwonek J., et al. Matrix metalloproteinase-9 is required for hippocampal late-phase long-term potentiation and memory. J Neurosci 26 (2006) 1923-1934
32. Noe V., Fingleton B., Jacobs K., Crawford H.C., Vermeulen S., Steelant W., et al. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J Cell Sci 114 (2001) 111-118
33. Quinones S., Saus J., Otani Y., Harris E.D., and Kurkinen M. Transcriptional regulation of human stromelysin. J Biol Chem 264 (1989) 8339-8344
34. Olson M.L., Meighan P.C., Brown T.E., Asay A.L., Benoist C.C., Harding J.W., et al. Hippocampal MMP-3 elevation is associated with passive avoidance conditioning. Regulatory Pept 146 (2008) 19-25
35. Overal J.E., and Gorhan D.R. The Brief Psychiatric Rating Scale. Psychol Rep 10 (1962) 799-812
36. Ozkurkcugil A., Aydemir O., Yildiz M., Esen Danaci A., Koroglu E., et al. DSM-IV eksen-I bozukluklari icin yapilandirilmasi klinik görüsmenin Türkce'ye uyarlanmasi ve güvenilirlik çalismasi. Ilac Tedavi Dergisi 12 (1999) 233-236
37. Rapoport J.L., Addington A.M., Frangou S., and Psych M.R. The neurodevelopmental model of schizophrenia: Update 2005. Mol Psychiatry 10 (2005) 434-449
38. Reeves T.M., Prins M.L., Zhu J., Povlishock J.T., and Phillips L.L. Matrix metalloproteinase inhibition alters functional and structural correlates of deafferentation-induced sprouting in the gentate gyrus. J Neurosci 23 (2003) 10182-10189
39. Risch N. The genetic epidemiology of cancer: interpreting family and twin studies and their implications for molecular genetic approaches. Cancer Epidemiol Biomarkers Prev 10 (2001) 733-741
40. Ross C.A., Margolis R.L., Reading S.A., Pletnikov M., and Coyle J.T. Neurobiology of schizophrenia. Neuron 52 (2006) 139-153
41. Schloesser R.J., Huang J., Klein P.S., and Manji H.K. Cellular plasticity cascades in the pathophysiology and treatment of bipolar disorder. Neuropsychopharmacology 33 (2008) 110-133
42. Schulze-Tanzil G., de Souza P., Merker H.J., and Shakibaei M. Co-localization of integrins and matrix metalloproteinases in the extracellular matrix of chondrocyte cultures. Histol Histopathol 16 (2001) 1081-1089
43. Simonsen C., Sundet K., Vaskinn A., Birkenaes A.B., Engh J.A., Hansen C.F., et al. Neurocognitive profiles in bipolar I and bipolar II disorder: differences in pattern and magnitude of dysfunction. Bipolar Disord 10 (2008) 245-255
44. Sklar P. Linkage analysis in psychiatric disorders: the emerging picture. Annu Rev Genomics Hum Genet 3 (2002) 371-413
45. Sternlicht M.D., and Werb Z. How matrix metalloproteinases regulate cell behavior. Annu Rev Cell Dev Biol 17 (2001) 463-516
46. Strakowski S.M., Delbello M.P., and Adler C.M. The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings. Mol Psychiatry 10 (2005) 105-116
47. Szklarczyk A., Lapinska J., Rylski M., McKay R.D., and Kaczmarek L. Matrix metalloproteinase-9 undergoes expression and activation during dendritic remodeling in adult hippocampus. J Neurosci 22 (2002) 920-930
48. Trysberg E., Blennow K., Zachrisson O., and Tarkowski A. Intrathecal levels of matrix metalloproteinases in systemic lupus erythematosus with central nervous system engagement. Arthritis Res Ther 6 (2004) R551-556
49. Tsuang M.T., and Faraone S.V. The genetics of mood disorders (1990), John Hopkins Press, Baltimore
50. Tsuang M.T., Winokur G., and Crowe R.R. Morbidity risks of schizophrenia and affective disorders among first degree relatives of patients with schizophrenia, mania, depression and surgical conditions. Brit J Psychiatry 137 (1980) 497-504
51. Vaillant C., Didier-Bazes M., Hutter A., Belin M.F., and Thomasset N. Spatiotemporal expression patterns of metalloproteinases and their inhibitors in the postnatal developing rat cerebellum. J Neurosci 19 (1999) 4994-5004
52. Valles V., Van Os J., Guillamat R., Gutierrez B., Campillo M., Gento P., et al. Increased morbid risk for schizophrenia in families of in-patients with bipolar illness. Schizophr Res 42 (2000) 83-90
53. VanSaun M., Humburg B.C., Arnett M.G., Pence M., and Werle M.J. Activation of matrix metalloproteinase-3 is altered at the frog neuromuscular junction following changes in synaptic activity. Dev Neurobiol 67 (2007) 1488-1497
54. Ventura J., Nuechterlein K.H., Subotnik K.L., Gutkind D., and Gilbert E.A. Symptom dimensions in recent-onset schizophrenia and mania: a principal components analysis of the 24-item Brief Psychiatric Rating Scale. Psychiatry Res 97 (2000) 129-135
55. Williams N.M., O'Donovan M.C., and Owen M.J. Genome scans and microarrays: converging on genes for schizophrenia?. Genome Biol 3 (2002) 1011.1-1011.5 [reviews]
56. Wright J.W., Meighan S.E., Murphy E.S., Holtfreter K.L., Davis C.J., Olson M.L., et al. Habituation of the head-shake response induces changes in brain matrix metalloproteinases-3 (MMP-3) and -9. Behav Brain Res 174 (2006) 78-85
57. Wright J.W., Brown T.E., and Harding J.W. Inhibition of hippocampal matrix metalloproteinase-3 and -9 disrupts spatial memory. Neural Plast 2007 (2007) 73813
58. Ye S., Watts G.F., Mandalia S., Humphries S.E., and Henney A.M. Preliminary report: genetic variation in the human stromelysin promoter is associated with progression of coronary atherosclerosis. Br Heart J 73 (1995) 209-215
59. Yong V.W. Metalloproteinases: mediators of pathology and regeneration in the CNS. Nat Rev Neurosci 6 (2005) 931-944
60. Young R.C., Bigss J.T., Ziegler V.E., and Meyer D.A. A rating scale for mania: reliability, validity, and sensitivity. Br J Psychiatry 133 (1978) 429-435